Abstract
Background The COVID-19 pandemic has dramatically changed medical practice worldwide. It posed a significant impact on different health services, including dermatology.
Methods and objectives Two online surveys were conducted to determine the prevalence of personal protective equipment-related skin complications (200 healthcare providers were included) and to demonstrate the outbreak’s impact on dermatology practice (100 dermatologists were included).
Results In the first survey, the response rate was 72.46%. PPE- related dermatoses were reported by 147 (73%) participants, including frictional dermatitis (51.9%), mechanical acne (33.1%), contact dermatitis (29.9%), nonspecific rash (17.5%), urticaria (9.1%) and skin infections (3.2%).
The response rate of the second survey was 64%. COVID-19 emerging cutaneous manifestations were recognized by 20% of dermatologists, including maculopapular rash (41.67%), urticaria (37.50%), chilblain (25%) and vasculitis (16.67). Telemedicine was provided by 73% of the dermatologists. The relapse rates of psoriasis, atopic dermatitis, rosacea, vitiligo and alopecia areata were noticeably increased as observed by 62%, 50%, 20%, and 4% of dermatologists, respectively. Most dermatologists (89%) reported minimal use of immunosuppressive drugs amid the pandemic.
Conclusions This article highlights the pivotal role of dermatologists in the leading edge during the current health crisis and how they adapt to these unfamiliar circumstances to meet the challenges. It documents the emergence of PPE-related dermatoses among healthcare providers and the impact of COVID-19 on different aspects of dermatology practice.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Non applicable
Funding Statement
Funding sources: None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Arab Board of Health Specialization, MOH Iraq
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Ethical approval: Arab Board of Health Specialization, MOH Iraq
Conflicts of interest: None
Funding sources: None
Patient privacy and ethical use of images: The patients in this manuscript have given written informed consent for publication of their case details, including the use of images.
Data Availability
The used surveys are available for readers.
https://drive.google.com/drive/folders/1eH6inpIkkWpkJVmHYVNqmxXaBXQo9bJN?usp=sharing
